McDonald’s (MCD) is loved for two reasons – burgers and market-beating earnings figures. The hamburger giant has set a standard for itself surpassing earnings estimates in the past two quarters and we see no reason why it shouldn’t repeat this in Q3 as well.
As the company reports third-quarter results on October 23, analysts on an average expect EPS of $1.98 on a revenue of $5.28 billion. Even analysts are quite bullish on the stock with 24 of them awarding a BUY rating. McDonald’s has an average price target of $183.29, which is at 9.7% upside from Friday’s mid-day trading price.
McDonald’s has been witnessing a decline in year-over-year sales over the past few quarters, but this was primarily due to the refranchising activities taken up by it. During the second quarter, revenue fell 12%, but this did not dent the company’s comparable sales, which grew a decent 4%. The company also reported an earnings surprise of 3.65%.
Revenue will, meanwhile, see more declines in the third quarter, as the burger chain continues to implement its restructuring strategy. Under this strategy, the fast food giant is cutting down on the number of company-owned outlets and replacing them with franchise outlets. While this strategy has helped in improving earnings, the topline is taking a hit in the short term.
However, reported comp sales have rallied over the past three years and should continue through the third quarter. Adding to that, the fact that the company has been focusing more on limited-period menus and other value offerings should also work in its favor.
In the retrospect, McDonald’s shouldn’t worry investors much following Q3 results and should easily be able to continue its momentum. The stock has been mostly flat in the past 52 weeks.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on